|
Match
|
Document |
Document Title |
|
|
6908907 |
Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
This invention provides for the prevention and treatment of tumor growth, metastasis, and cancer-mediated thrombosis through the administration, in combination, of a short or long acting GPIIb/IIIa...
|
|
|
RE38743 |
Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated...
|
|
|
6894022 |
Growth factor modified protein matrices for tissue engineering
Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling, and/or drug delivery. The proteins can be incorporated so that they are...
|
|
|
6844329 |
Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing...
|
|
|
6828307 |
Low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity
The invention concerns the use of a sulphated polysaccharide capable of being obtained by radical depolymerization of a raw fucan derived from Pheophyceae, said polysaccharide having a molar mass...
|
|
|
6812221 |
FGF-affinity chromatography
The present invention relates to a method and apparatus for isolating anticoagulant heparin or heparan sulfate by binding the anticoagulant heparin or anticoagulant heparan sulfate onto an affinity...
|
|
|
6809086 |
Process for producing desulfated polysaccharide, and desulfated heparin
A method of increasing proliferation of cells which comprises adding to cells a cellular proliferating amount of a primary hydroxyl group of N-acetylglucosamine selectively desulfated heparin...
|
|
|
6797705 |
Rhamnan sulphate composition for treatment of endothelial dysfunction
The invention described is a method and composition for inducing cell surface anti-thrombotic activity in endothelial cells comprising administering to a patient a therapeutically-effective amount...
|
|
|
6793921 |
Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers
The present invention provides specific antibodies obtained from eggs laid by hens which have been immunized against urease of Helicobacter pylori as an antigen, and specific antibodies obtained...
|
|
|
6787365 |
Inhibition of L-selectin and P-selectin mediated binding using heparin
The present invention provides methods of inhibiting L-selectin and P-selectin mediated binding in a subject by administering heparin to the subject in an amount that does not produce substantial...
|
|
|
6777398 |
Process for the preparation of chondroitin sulfates from K4 polysaccharide and obtained products
New process for the preparation of chondroitin sulfates from the bacterial origin polysaccharide named K4, by defructosilation followed by selective sulfation.
|
|
|
6770292 |
Pharmaceutical compositions for oral administration
A method for oral administration of an active principle includes the steps of incorporating an active principle in multilamellar vesicles having a diameter of between 0.1 and 25 μm, and a lamellar...
|
|
|
6756364 |
Method of reducing gastrointestinal side effects associated with orlistat treatment
A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.
|
|
|
6726923 |
Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts
This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods...
|
|
|
6723344 |
Controlled release of non heparin-binding growth factors from heparin-containing matrices
Matrices that support cell adhesion and growth are disclosed that deliver low heparin-binding affinity growth factor protein peptides in a controlled manner. These matrices comprise covalently or...
|
|
|
6699484 |
Fibrin sealants or adhesives comprising a hyaluronic acid derivative material
An especially useful fibrin glue composition comprises a biocompatible, bioabsorbable hyaluronic acid derivative material, upon which are applied or chemically bonded fibrinogen and thrombin, along...
|
|
|
6693073 |
Pulmonary delivery of active agents
The present invention provides methods for administering an active agent to an animal in need of the agent by the pulmonary route. This method comprises administering via the pulmonary route, a...
|
|
|
6692772 |
Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.
|
|
|
6670339 |
Use of sulfated oligosaccharides in lowering blood triglyceride levels
The present invention relates generally to sulfated oligosaccharides, and in particular to the use of certain sulfated oligosaccharides as agents for lowering blood levels of triglycerides such as,...
|
|
|
6656922 |
Oral delivery of macromolecules
Polysaccharides, which are widely used as an anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong...
|
|
|
6632801 |
Method and composition for inhibiting human cholesterol esterase
A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight...
|
|
|
6630171 |
Particles based on polyamino-acid(s) and methods for preparing same
The invention concerns delivery particles (DP's) for active principles (AP's) based on linear amphiphilic polyamino-acids (PAA's), with α-peptide chains, capable of being spontaneously formed by...
|
|
|
6630458 |
Teat dipping agent
Use of a composition comprising chitosan in combination with a polysaccharide selected from heparin, heparan sulphate and dextran sulphate, as an active component in a solvent, for the manufacture...
|
|
|
6630154 |
Polymer formulations containing perfluorinated compounds for the engineering of cells and tissues for transplantation that improves cell metabolism and survival, and methods for making same
Disclosed and claimed are: a composition including at least one glycosaminoglycan, e.g., CIS, at least one perfluorinated substance and at least one alginate, e.g., sodium alginate, wherein: the...
|
|
|
6617316 |
Oligosaccharides, their preparation and pharmaceutical compositions containing them
The present invention relates to oligosaccharides of formula: to mixtures thereof, to diastereoisomers thereof, to a process for preparing them, to pharmaceutical compositions containing them,...
|
|
|
6608042 |
Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
The present invention relates to pharmaceutical compositions containing as an active ingredient at least one oligosaccharide of formula: to novel oligosaccharides of formula (I), to mixtures...
|
|
|
6608044 |
Inhibition of TNF activity
The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the...
|
|
|
6596705 |
Inhibition of L-selectin and P-selection mediated binding using heparin
The present invention provides methods of inhibiting L-selectin and P-selectin mediated binding in a subject by administering heparin to the subject in an amount that does not produce substantial...
|
|
|
6596261 |
Method of administering a medicinal aerosol formulation
A method of treating in a human or animal a condition capable of treatment by oral or nasal inhalation has been found. The method comprises administering a medicinal aerosol formulation comprising...
|
|
|
6596699 |
Nucleic acid coating compositions and methods
A nucleic acid coating composition including a polyanion bound, directly or through one or more intermediates, to a medical device surface, with a condensate comprising a polycation and nucleic...
|
|
|
6592891 |
Plaster for topical use containing heparin and diclofenac
Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix...
|
|
|
6589943 |
Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption
Formulations for enhanced mucosal absorption of heparin are disclosed. In one embodiment, a powdered heparin composition is made by dissolving an amphiphilic heparin derivative including heparin...
|
|
|
6579858 |
Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas
Cerebral edema is prevented and treated by administering an effective amount of a low molecular weight heparin.
|
|
|
6569840 |
Low-molecular heparin modification and remedy for skin ulcer
The invention is direct to modified heparins, especially low-molecular weight modified heparins that are adapted for used in preparing an agent for treating a skin ulcer. The low-molecular weight...
|
|
|
6569839 |
Fast-acting pharmaceutical compositions and methods of use
A pharmaceutical composition comprising at least one local anesthetic, at least one anti-inflammatory agent and at least one antibiotic are disclosed. The local anesthetic has a peak effect no...
|
|
|
6559132 |
Composition comprising heparin as a non-thrombogenic surface coating agent
The present invention relates to a composition comprising heparin to be used as a non-thrombogenic surface when in contact with arterial blood flow. It also relates to a device treated on the...
|
|
|
6559133 |
Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes
A method for treatment of a vascular or cardiovascular condition or acute coronary syndromes comprises administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a...
|
|
|
6559131 |
Use of fucane for regulating the reconstruction of connective tissue
The invention concerns the use of fucanes for obtaining medicines for modulating metalloprotease and inhibiting leukocytic elastase. Said medicines help activate collagen synthesis inhibit...
|
|
|
6537524 |
Combinations of formoterol and a tiotropium salt
A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) a tiotropium salt of a pharmaceutically...
|
|
|
6537977 |
Anti-inflammatory agent
A pharmaceutical composition, which contains glycosaminoglycan having at least one sulfate group or a pharmaceutically acceptable salt thereof, and an immunosuppressant.
|
|
|
6528273 |
Methods for quality control of prothrombin time (PT) and activated partial thromboplastin time (APTT) assays using coagulation controls
Coagulation control compositions suitable for use in connection with PT and/or APTT assays are disclosed along with their methods of preparation and methods of use. Preferred coagulation controls...
|
|
|
6495530 |
Composition for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
The present invention is directed to a composition comprising a therapeutically effective amount of exogenous heparin and arginine or physiologically acceptable salts thereof which is used in the...
|
|
|
6489311 |
Method for the prevention of apoptosis
Heparin reduces ischemia-reperfusion injury to myocardium. This effect has been attributed complement inhibition, but heparin also has other activities that might diminish ischemia-reperfusion. To...
|
|
|
6489289 |
Method for establishing a dosage plan for thrombin inhibitors
After a standard dose of a hirudin or an oral thrombin inhibitor is given to a recipient, the concentration of the hirudin or oral thrombin inhibitor in the blood of the recipient is determined...
|
|
|
6486140 |
Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site
The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate for the manufacture of an agent capable of preventing or substantially...
|
|
|
6482806 |
Product of heat treatment of uronic acid, food, drink, or drug including the product
A product obtained by heating at least one substance selected from the following (a), (b) and (c). (a) uronic acid or uronic acid derivative; (b) a saccharide compound containing uronic acid or a...
|
|
|
6472379 |
Angiogenesis inhibition
Angiogenesis is inhibited by the local administration of a pharmaceutical preparation formed from the reaction of hyaluronic acid, carboxymethylcellulose and a carbodiimide. The preparation, which...
|
|
|
6458383 |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
A delayed release pharmaceutical dosage form for oral administration of a hydrophilic drug, e.g., a polysaccharide drug such as low molecular weight heparin, are provided. The dosage form comprises...
|
|
|
6451767 |
Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 , are each, independently,...
|
|
|
6440947 |
Method for treating occlusive peripheral vascular disease and coronary disease
Compositions and methods for treatment of occlusive peripheral vascular disease and coronary disease are disclosed. The compositions and methods allow treatment of diseases associated with...
|